Stay updated on Nivolumab/Daratumumab in Multiple Myeloma Clinical Trial
Sign up to get notified when there's something new on the Nivolumab/Daratumumab in Multiple Myeloma Clinical Trial page.

Latest updates to the Nivolumab/Daratumumab in Multiple Myeloma Clinical Trial page
- Check5 days agoNo Change Detected
- Check12 days agoChange DetectedRevision label updated from v3.6.2 to v3.6.3 on the page, representing a small metadata update to the page.SummaryDifference0.0%

- Check19 days agoChange DetectedThe study page was updated from revision v3.6.0 to v3.6.2, signaling a maintenance update to the page. It does not alter the study details, eligibility criteria, or results.SummaryDifference0.0%

- Check33 days agoChange DetectedThe page now shows that recruitment is closed, indicating no new participants will be enrolled. This clarifies the study's current status for participants and investigators reviewing eligibility and enrollment options.SummaryDifference0.3%

- Check41 days agoChange DetectedThe page's revision tag was updated from v3.5.4 to v3.5.5, signaling a minor site update.SummaryDifference0.0%

- Check62 days agoChange DetectedThe page now displays Revision: v3.5.4, replacing the previous v3.5.3, indicating a new site/template revision has been applied. This appears to be a minor metadata update rather than a change to study content.SummaryDifference0.0%

- Check83 days agoChange DetectedThe page’s footer revision/version has been updated from v3.5.2 to v3.5.3, indicating a site release rather than a change to the study’s content.SummaryDifference0.0%

Stay in the know with updates to Nivolumab/Daratumumab in Multiple Myeloma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Nivolumab/Daratumumab in Multiple Myeloma Clinical Trial page.